Status:
UNKNOWN
Levels of Pigment Epithelium-derived Factor in Patients With Psoriasis.
Lead Sponsor:
Sohag University
Conditions:
Psoriasis
Eligibility:
All Genders
Phase:
NA
Brief Summary
Psoriasis is an immune-mediated chronic inflammatory skin disease associated with increase interaction of inflammatory mediators like adipokines. Pigment epithelium-derived factor (PEDF) is one of the...
Eligibility Criteria
Inclusion
- Patients with psoriasis and group of age and sex-matched healthy volunteers will be included as a control group.
Exclusion
- Pregnancy.
- Patients with other inflammatory skin disorders.
- Patients on antioxidants or anti-inflammatory drugs.
- Patients on topical or systemic treatment for psoriasis in the last 4 weeks prior to enrollment in the study.
- Patients on systemic retinoids (Acitretin).
- Obesity: body mass index (BMI ) \> 30.
- Malignancies e.g squamous cell carcinoma.
- Viral warts.
- Diabetes.
- Hypertension.
Key Trial Info
Start Date :
February 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT05252741
Start Date
February 20 2022
End Date
September 1 2023
Last Update
April 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine Sohag University
Sohag, Egypt